Know Cancer

or
forgot password

Urinary VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence


N/A
18 Years
N/A
Not Enrolling
Both
Glioblastoma

Thank you

Trial Information

Urinary VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence


Measurement of urinary VEGF levels pre treatment,immediately after treatment, and 1 month
after treatment


Inclusion Criteria:



- Patient must be enrolled on an RTOG GBM study that prescribes 6000 cGy of radiation
therapy.

- Patient must meet the eligibility requirements for the RTOG treatment study. (If the
patient is deemed retrospectively ineligible for the RTOG treatment study, the
patient will likewise be ineligible for this study.)

- Patient must sign a study-specific informed consent for RTOG 0611 prior to study
entry.

Exclusion Criteria:

- Patient not able to receive 6000 cGy of radiation therapy.

Type of Study:

Observational

Study Design:

Observational Model: Defined Population, Observational Model: Natural History, Time Perspective: Longitudinal, Time Perspective: Prospective

Principal Investigator

Deborah T Blumenthal, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Tel-Aviv Sourasky Medical Center

Authority:

Israel: Ministry of Health

Study ID:

RTOG0611

NCT ID:

NCT00392548

Start Date:

October 2006

Completion Date:

October 2006

Related Keywords:

  • Glioblastoma
  • GBM
  • glioblastoma
  • urine
  • VEGF
  • radiation
  • Patients must be enrolled to an RTOG GBM study that prescribes 6000 cGy of radiation therapy.
  • Glioblastoma

Name

Location